Hepatitis A is an infectious disease frequently reported in the United States. An average of
26,000 cases were reported each year during 1980 to 1999; probably 3 times as many …

… The question of whether hepatitis A vaccine can be used for postexposure prophylaxis is …
We believe that hepatitis A vaccine should be given to persons who have evidence of …

Clinical trials of an inactivated hepatitis A vaccine have encompassed 104 studies completed
by December 1993 in 27 countries. Studies involved 50,677 subjects and administration of…

… We investigated the use of hepatitis A vaccine to prevent secondary infections with hepatitis
… We did a randomised controlled trial of hepatitis A vaccine in household contacts of people …

… hepatitis A vaccine. Among initially seronegative recipients of two doses of hepatitis A vaccine…
Following two doses of hepatitis A vaccine (days 138 through 386), protective efficacy was …

Hepatitis A continues to cause sporadic cases, epidemics, and occasional deaths in the
United States. A killed virus vaccine for immunization against hepatitis A has recently been …

Although episodes of jaundice have been recognized since the time of Hippocrates, the
earliest outbreaks that on epidemiologic grounds seem likely to have been hepatitis A occurred …

… We included trials assessing the effects of any type of hepatitis A vaccine (attenuated or
inactivated), irrespective of route of administration, dosage, and schedule compared with …

… mass immunization of susceptible persons with 1 dose of an inactivated hepatitis A vaccine.
… Hepatitis A vaccine was offered to all persons in susceptible age groups in villages with …

Immunopotentiating reconstituted influenza virosomes (IRIV) are efficient carrier systems for
small virion particles such as hepatitis A virus (HAV). We evaluated immunogenicity and …